David M. Barrett, MD, PhD
Both prior chemotherapy and a dependence on glycolysis appear to reduce the potential to develop T cells into chimeric antigen receptor (CAR) T-cell therapy.
Oxygen consumption rate (OCR) analysis revealed a poor spare respiratory capacity (SRC) in the T cell samples that go on to perform poorly as CAR T cells. Nanostring RNA profiling of metabolic pathways showed that the poor performing samples were more likely to use glycolysis as a fuel source, rather than fatty acids.
... to read the full story